{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:35:52Z","timestamp":1758080152446,"version":"3.44.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Alzheimer's disease poses intricate challenges, affecting cognition and behavior, notably marked by agitation. The FDA's approval of brexpiprazole, an atypical antipsychotic, stands as a milestone, representing the first treatment for Alzheimer's-related agitation. brexpiprazole's modulation of serotonin-dopamine activity has proven effective in clinical trials, reducing agitation as measured by CMAI scores. Gradual dosage escalation is recommended, with potential side effects including nasopharyngitis, urinary tract infections, dizziness, somnolence, headache, and insomnia. Also useful for schizophrenia and treatment-resistant depression, providing ongoing treatment and potential well-being enhancement by managing agitation and other symptoms.<\/jats:p>","DOI":"10.1177\/25424823251379881","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:53:17Z","timestamp":1758045197000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Brexpiprazole: Pioneering medication for managing agitation in Alzheimer's disease"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1541-3037","authenticated-orcid":false,"given":"Ayesha","family":"Shaukat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-0183","authenticated-orcid":false,"given":"Rumaisa","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6853-8024","authenticated-orcid":false,"given":"Nawal","family":"Khaliq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3900-4419","authenticated-orcid":false,"given":"Zubayer","family":"Shams","sequence":"additional","affiliation":[{"name":"Brunel medical school, Brunel University, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-1215","authenticated-orcid":false,"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[{"name":"Department of research, Medical Research Circle (MedReC), Goma, Democratic Republic of the Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215699"},{"key":"e_1_3_3_3_2","unstructured":"Dementia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia (accessed 2 September 2025)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155150"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00175"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-023-03328-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104795"},{"key":"e_1_3_3_8_2","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s Facts and Figures Report https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures (accessed 2 September 2025)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.09.009"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000417403"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/153331750101600306"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2410"},{"key":"e_1_3_3_13_2","unstructured":"FDA approves Rexulti for agitation tied to Alzheimer\u2019s dementia | Daily therapy is first to be approved for this use in US | Alzheimer\u2019s News Today https:\/\/alzheimersnewstoday.com\/news\/fda-approves-rexulti-agitation-associated-alzheimers-dementia\/ (accessed 2 September 2025)."},{"key":"e_1_3_3_14_2","unstructured":"Brexpiprazole: Uses Interactions Mechanism of Action | DrugBank Online https:\/\/go.drugbank.com\/drugs\/DB09128 (accessed 2 September 2025)."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315614739"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852915000954"},{"key":"e_1_3_3_17_2","article-title":"Aripiprazole versus brexpiprazole for people with schizophrenia","volume":"2023","author":"Mart\u00ednez-V\u00e9lez NA","year":"2023","unstructured":"Mart\u00ednez-V\u00e9lez NA, Escamilla Orozco RI, Flores Medina Y, et al. Aripiprazole versus brexpiprazole for people with schizophrenia. Cochrane Database Syst Rev 2023; 2023: CD014670.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_18_2","unstructured":"Fda. REXULTI (brexpiprazole) tablets for oral use www.fda.gov\/medwatch. (accessed 2 September 2025)."},{"key":"e_1_3_3_19_2","unstructured":"Study Details | NCT03548584 | A Trial to Evaluate the Safety Efficacy and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer\u2019s Type | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03548584 (accessed 2 September 2025)."},{"key":"e_1_3_3_20_2","unstructured":"FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer\u2019s Disease | FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease (accessed 2 September 2025)."},{"key":"e_1_3_3_21_2","unstructured":"Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of supplemental New Drug Application (sNDA) for REXULTI\u00ae (brexpiprazole) for the Treatment of Agitation Associated with Dementia due to Alzheimer\u2019s Disease \uff5cMay 11 2023\uff5cNews Releases | Otsuka Pharmaceutical Co. Ltd. https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2023\/20230511_1.html (accessed 2 September 2025)."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13030397"},{"key":"e_1_3_3_23_2","unstructured":"Brexpiprazole Side Effects: Common Severe Long Term. https:\/\/www.drugs.com\/sfx\/brexpiprazole-side-effects.html (accessed 2 September 2025)."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.644317"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251379881","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823251379881","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251379881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:53:18Z","timestamp":1758045198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823251379881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"alternative-id":["10.1177\/25424823251379881"],"URL":"https:\/\/doi.org\/10.1177\/25424823251379881","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"25424823251379881"}}